Guy. A. Higgins - Toxicology

Author Information

Guy A. Higgins is a distinguished researcher affiliated with InterVivo Solutions Inc. in Toronto, Canada, and the Department of Pharmacology & Toxicology at the University of Toronto. His work prominently focuses on the pharmacological and toxicological aspects of various compounds, with a notable interest in their implications for mental health and addiction treatment.

Research Contributions

Guy A. Higgins has made significant contributions to the field of neuropharmacology and toxicology through his research on the effects of various pharmaceutical agents on behavior and neurological conditions. His studies often explore the potential therapeutic applications of receptor agonists and antagonists, particularly within the context of addiction and neurological disorders. His recent work includes investigations into the antidepressant properties of low doses of psilocybin and ketamine, as well as exploring the therapeutic potential of 5-HT2A and 5-HT2C receptors in treating nicotine dependence.

Aliases

Guy A. Higgins is also known by several aliases in academic publications, including Guy. A. Higgins, G. A. Higgins, G. Higgins, and Guy Higgins, among others. These variations can be attributed to different citation styles and journal requirements.

Publication and Citation Metrics

Metric	Value
Total Citation Count	9103
h-index	58
Total Paper Count	162

Publications:

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property

DOI: 10.3389/fphar.2021.640241

Year: 2021

5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence.

DOI: 10.1016/bs.pbr.2021.01.007

Year: 2021

Contrasting effects of d-amphetamine and atomoxetine on measures of impulsive action and choice

DOI: 10.1016/j.pbb.2021.173220

Year: 2021

Effects of 5-HT2C receptor modulation and the NA reuptake inhibitor atomoxetine in tests of compulsive and impulsive behaviour

DOI: 10.1016/j.neuropharm.2020.108064

Year: 2020

Characterization of Amphetamine, Methylphenidate, Nicotine, and Atomoxetine on Measures of Attention, Impulsive Action, and Motivation in the Rat: Implications for Translational Research

DOI: 10.3389/fphar.2020.00427

Year: 2020

Evaluation of Selective 5-HT2C Agonists in Acute Seizure Models.

DOI: 10.1021/acschemneuro.8b00739

Year: 2019

Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential.

DOI: 10.1016/j.pharmthera.2019.107417

Year: 2019

Preclinical evidence for combining the 5‐HT2C receptor agonist lorcaserin and varenicline as a treatment for nicotine dependence

DOI: 10.1111/adb.12602

Year: 2019

Novel KV7 ion channel openers for the treatment of epilepsy and implications for detrusor tissue contraction.

DOI: 10.1016/j.bmcl.2018.09.036

Year: 2018

Effects of the NMDA receptor antagonists dizocilpine and Ro 63-1908 on delay-discounting and risky decision-making in a gambling task

DOI: 10.1016/j.bbr.2018.04.028

Year: 2018

What is Reduced Uptake in Toxicology?

How Do Manufacturers Conduct Toxicity Testing?

What are In Silico Techniques?

How Do Carotenoids Interact with Other Nutrients and Drugs?

What happens during Phase I metabolism?

What Are the Sources of EDCs in Aquatic Environments?

Can Nutritional Deficiencies from Toxins Lead to Fractures?

What Role Does Labeling Play in Emergency Situations?

What is Hemolytic Uremic Syndrome (HUS)?

What is Active Immunity?

Partnered Content Networks

Relevant Topics